Prostate-Specific Antigen Testing in Tyrol, Austria: Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data up to 2008

DSpace/Manakin Repository

Prostate-Specific Antigen Testing in Tyrol, Austria: Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data up to 2008

Citable link to this page

 

 
Title: Prostate-Specific Antigen Testing in Tyrol, Austria: Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data up to 2008
Author: Oberaigner, Willi; Horninger, Wolfgang; Klocker, Helmut; Bektic, Jasmin; Schäfer, Georg; Frauscher, Ferdinand; Schennach, Harald; Bartsch, Georg; Siebert, Uwe

Note: Order does not necessarily reflect citation order of authors.

Citation: Oberaigner, Willi, Uwe Siebert, Wolfgang Horninger, Helmut Klocker, Jasmin Bektic, Georg Schäfer, Ferdinand Frauscher, Harald Schennach, and Georg Bartsch. 2012. Prostate-specific antigen testing in Tyrol, Austria: Prostate cancer mortality reduction was supported by an update with mortality data up to 2008. International Journal of Public Health 57(1): 57-62.
Full Text & Related Files:
Abstract: Objectives: The objective of this study was to update an in-depth analysis of the time trend for prostate cancer (PCA) mortality in the population of Tyrol by 5 years, namely to 2008. In Tyrol, prostate-specific antigen (PSA) tests were introduced in 1988/89; more than three-quarters of all men in the age group 45–74 had at least one PSA test in the past decade. Methods: We applied the same model as in a previous publication, i.e., an age-period-cohort model using Poisson regression, to the mortality data covering more than three decades from 1970 to 2008. Results: For Tyrol from 2004 to 2008 in the age group 60+ period terms show a significant reduction in prostate cancer mortality with a risk ratio of 0.70 (95% confidence interval 0.57, 0.87) for Tyrol, and for Austria excluding Tyrol a moderate reduction with a risk ratio of 0.92 (95% confidence interval 0.87, 0.97), each compared to the mortality rate in the period 1989–1993. Conclusions: This update strengthens our previously published results, namely that PSA testing offered to a population at no charge can reduce prostate cancer mortality. The extent of mortality reduction is in line with that reported in the other recent publications. However, our data do not permit us to fully assess the harms associated with PCA screening, and no recommendation for PSA screening can be made without a careful evaluation of overdiagnosis and overtreatment.
Published Version: doi:10.1007/s00038-011-0266-4
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281998/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10336900
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters